Finally, in many tumors, including gliomas and glioblastomas, L1CAM does support proliferation and invasiveness, and is thus envisaged as a biomarker of poor prognosis and a target of specific anti-tumor therapy (Suzuki et al. 2005; Siesser and Maness 2009; Schafer and Altevogt 2010; Cheng et al. 2011). Here, L1CAM is linked to glioma.